Applied Materials Inc. (AMAT) Financials Nov 20, 2014, 5:32
Applied Materials Inc. (AMAT) Financials Nov 20, 2014, 5:32 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Applied Materials Inc.
Fiscal year is November-October. All values USD millions. 2010 2011 2012 2013 2014 5-year trend
Sales/Revenue 9.55B 10.52B 8.72B 7.51B 9.07B
Cost of Goods Sold (COGS) incl. D&A 5.5B 6.16B 5.43B 4.57B 5.23B
COGS excluding D&A 5.19B 5.91B 5.01B 4.16B 4.85B
Depreciation & Amortization Expense 304.52M 246M 422M 410M 375M
Depreciation 191.52M 194M 198M 211M -
Amortization of Intangibles 113M 52M 224M 199M -
Gross Income 4.05B 4.36B 3.29B 2.94B 3.84B
2010 2011 2012 2013 2014 5-year trend
SG&A Expense 2.06B 2B 2.08B 2.22B 2.32B
Research & Development 1.14B 1.12B 1.24B 1.32B 1.43B
Other SG&A 921.26M 882M 848M 896M 890M
Other Operating Expense 0 0 0 0 -
Unusual Expense 613.83M (7M) 809M 328M 5M
EBIT after Unusual Expense (613.83M) 7M (809M) (328M) (5M)
Non Operating Income/Expense 4.56M 43M 0 32M -
Non-Operating Interest Income 32.87M 26M 17M 19M 23M
Equity in Affiliates (Pretax) 0 0 - 0 -
Interest Expense 21.51M 59M 95M 95M 95M
Gross Interest Expense 21.51M 59M 95M 95M 95M
Interest Capitalized 0 0 0 0 -
Pretax Income 1.39B 2.38B 316M 350M 1.45B
Income Tax 449.1M 452M 207M 94M 342M
Income Tax - Current Domestic 496.92M 295M 82M 5M -
Income Tax - Current Foreign 133.75M 206M 75M 72M -
Income Tax - Deferred Domestic (186.1M) (26M) 54M 36M -
Income Tax - Deferred Foreign 4.54M (23M) (4M) (19M) -
Income Tax Credits - - 0 0 -
Equity in Affiliates - - 0 0 -
Other After Tax Income (Expense) 0 0 0 0 -
Consolidated Net Income 937.87M 1.93B 109M 256M 1.11B
Minority Interest Expense 0 0 0 0 -
Net Income 937.87M 1.93B 109M 256M 1.11B
Extraordinaries & Discontinued Operations 0 0 0 0 -
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 -
Cumulative Effect - Accounting Chg 0 0 0 0 -
Discontinued Operations 0 0 0 0 -
Net Income After Extraordinaries 937.87M 1.93B 109M 256M 1.11B
Preferred Dividends 0 0 0 0 -
Net Income Available to Common 937.87M 1.93B 109M 256M 1.11B
EPS (Basic) 0.70 1.46 0.09 0.21 0.91
Basic Shares Outstanding 1.34B 1.32B 1.27B 1.2B 1.22B
EPS (Diluted) 0.70 1.45 0.09 0.21 0.90
Diluted Shares Outstanding 1.35B 1.33B 1.28B 1.22B 1.23B
EBITDA 2.29B 2.61B 1.63B 1.13B 1.9B
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...
Continue Reading
Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...
Continue Reading
Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...
Continue Reading
Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....
Continue Reading
The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...
Continue Reading
The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...
Continue Reading
Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...
Continue Reading
GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...
Continue Reading
Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...
Continue Reading
Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...
Continue Reading
Top 5 Most Recently Viewed Articles
ANI Pharmaceuticals Set for Key Presentation at Biotech Conference ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is gearing up to showcase its advancements at the Guggenheim Biotech Conference. On an exciting date, Nikhil Lalwani, the Company’s President and CEO, along with Stephen Carey, the CFO, will host a fireside chat to discuss the latest developments and future plans...
Continue Reading
Reviving the North Shore Economy, One Shuttle Ride at a Time Not every day do you see a $5 investment with such community punch. On June 29, a new bus service launches, whisking folks from Waik?k? and Ko Olina to O?ahu’s North Shore. But this ain't just another tourist bus ride—it's a lifeline for local businesses hit hard by March's kona low storms. Connecting...
Continue Reading
Virginia Cancer Specialists Expands its Reach with a New Center Virginia Cancer Specialists, a leading private cancer practice in the region, has announced the opening of their newly expanded cancer center. This important development aims to enhance patient care and provide access to the latest cancer treatments. The expansion not only signifies growth but also a...
Continue Reading
Important Financial Calendar for TCM Group A/S TCM Group A/S is a significant player in the kitchen and furniture manufacturing industry. As the year approaches its end, the company has established key dates for reporting and annual meetings, signaling to shareholders and stakeholders the importance of staying informed. Scheduled Report Releases and Meetings The Board of...
Continue Reading
Understanding the Recent Chicago PMI Decline Recently, the Chicago Purchasing Managers' Index (PMI) reported a surprising score of 36.9, highlighting ongoing challenges in the manufacturing sector within the region. This score is a clear indication that the manufacturing landscape in Chicago is experiencing significant contraction, a worrisome sign for the local and...
Continue Reading